Suppr超能文献

依托度酸的临床药代动力学。

Etodolac clinical pharmacokinetics.

作者信息

Brocks D R, Jamali F

机构信息

SmithKline Beecham Pharmaceuticals, Drug Metabolism and Pharmacokinetics, King of Prussia, Pennsylvania.

出版信息

Clin Pharmacokinet. 1994 Apr;26(4):259-74. doi: 10.2165/00003088-199426040-00003.

Abstract

Etodolac is a chiral nonsteroidal anti-inflammatory drug (NSAID) that is marked as the racemate. Currently, the drug is available in several countries for the treatment of arthritis and the alleviation of pain. Etodolac possesses several unique disposition features mainly due to its stereoselective pharmacokinetics. In plasma, the concentrations of the 'inactive' R-enantiomer are about 10-fold higher than those of the active S-enantiomer, an observation that is novel among the chiral NSAIDs. In common with other NSAIDs, the drug is highly plasma protein bound, and undergoes virtually complete biotransformation to oxidised metabolites and acyl-glucuronides. Etodolac is well absorbed, with maximal plasma concentrations attained within 1 to 2 hours in healthy volunteers. The area under the plasma concentration-time curve of racemic etodolac increases linearly with doses used clinically. The elimination half-life of etodolac is between 6 and 8 hours in plasma, and is similar for both enantiomers. The volume of distribution (Vd) of racemic etodolac is higher than that of most other NSAIDs mainly because of the extensive distribution of the S-enantiomer. The very large Vd of the S-enantiomer, compared with its antipode is, at least in part, due to its less extensive plasma protein binding. In addition to the unchanged drug, substantial concentrations of the acyl-glucuronides of etodolac are found in both plasma and the synovial fluid of patients with arthritis. A limited amount of conjugated etodolac is found in the bile of patients following cholecystectomy. Hepatic cirrhosis has no effect on the pharmacokinetics of racemic etodolac, although the effect of hepatic dysfunction on the pharmacokinetics of the individual enantiomers has yet to be determined. In elderly non-arthritic individuals with excellent kidney function, aging does not affect the pharmacokinetics of etodolac. The pharmacokinetics of the drug in patients with renal failure have not been published, and may be important because the acyl-glucuronides are renally cleared.

摘要

依托度酸是一种手性非甾体抗炎药(NSAID),以消旋体形式上市。目前,该药物在多个国家可用于治疗关节炎和缓解疼痛。依托度酸具有一些独特的处置特性,主要归因于其立体选择性药代动力学。在血浆中,“无活性”的R-对映体浓度比活性S-对映体高约10倍,这一观察结果在 chiral NSAIDs 中是新颖的。与其他NSAIDs一样,该药物与血浆蛋白高度结合,并几乎完全生物转化为氧化代谢物和酰基葡萄糖醛酸。依托度酸吸收良好,健康志愿者在1至2小时内达到最大血浆浓度。消旋依托度酸的血浆浓度-时间曲线下面积随临床使用剂量呈线性增加。依托度酸在血浆中的消除半衰期为6至8小时,两种对映体相似。消旋依托度酸的分布容积(Vd)高于大多数其他NSAIDs,主要是因为S-对映体分布广泛。与其对映体相比,S-对映体的Vd非常大,至少部分是由于其血浆蛋白结合较少。除了未改变的药物外,在关节炎患者的血浆和滑液中都发现了大量依托度酸的酰基葡萄糖醛酸。胆囊切除术后患者的胆汁中发现了少量结合型依托度酸。肝硬化对消旋依托度酸的药代动力学没有影响,尽管肝功能障碍对各个对映体药代动力学的影响尚未确定。在肾功能良好的老年非关节炎个体中,衰老不影响依托度酸的药代动力学。该药物在肾衰竭患者中的药代动力学尚未发表,可能很重要,因为酰基葡萄糖醛酸通过肾脏清除。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验